Owlstone Medical in Frontline Genomics’ Liquid Biopsy Report
Published on: 20 Feb 2023
Owlstone Medical is excited to see our innovative solution for non-invasive metabolite detection and identification, Breath Biopsy® featured in Frontline Genomics’ Liquid Biopsy Report.
Breath Biopsy is a revolutionary method for detecting disease biomarkers in a patient’s breath. By analyzing volatile organic compounds (VOCs) present in exhaled breath, our technology can detect and identify metabolites associated with early signs of disease, with the potential to provide clinicians with a valuable tool for diagnosing and monitoring a wide range of conditions.
The inclusion of Breath Biopsy in Frontline Genomics’ Liquid Biopsy Report is a testament to the growing interest in non-invasive diagnostic tools. Our technology provides a unique and valuable alternative to liquid biopsy, which can provide critical insights into disease progression and treatment response without the need for invasive procedures.
The report examines the latest developments and trends in liquid biopsy, which involves analyzing a patient’s blood or other bodily fluids for biomarkers that can indicate the presence of disease. While Breath Biopsy is not a traditional liquid biopsy, it falls under this umbrella term as it analyzes a patient’s breath for biomarkers.
Breath Biopsy has already demonstrated its potential in the detection of a wide range of compounds associated with diseases, including cancer, inflammatory bowel disease, and respiratory infections. By enabling earlier and more accurate diagnosis, our technology has the potential to save lives and reduce the burden on healthcare systems worldwide.
At Owlstone Medical, we are committed to advancing the field of non-invasive diagnostics through our cutting-edge technology and extensive research collaborations. We believe that Breath Biopsy represents the future of disease detection and are excited to see its potential recognized in Frontline Genomics’ Liquid Biopsy Report.
